

# PROACTIVE: prostate cancer support intervention for active surveillance

<b>Submission date</b> 11/06/2015	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/07/2015	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 06/08/2024	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-support-programme-for-men-with-prostate-cancer-pro-active>

## Contact information

### Type(s)

Public

### Contact name

Dr Sam Watts

### Contact details

Primary Medical Care  
Aldermoor Health Centre  
Aldermoor Close  
Southampton  
United Kingdom  
SO16 5ST  
+44 (0)7766 480 993  
sw1u09@soton.ac.uk

### Type(s)

Scientific

### Contact name

Dr Sam Watts

### Contact details

Primary Medical Care  
Aldermoor Health Centre  
Aldermoor Close

Southampton  
United Kingdom  
SO16 5ST  
07766 480 993  
sw1u09@soton.ac.uk

## Additional identifiers

### Protocol serial number

1

## Study information

### Scientific Title

PROstate Cancer Support Intervention for ACTIVE Surveillance: a mixed methods randomized parallel-group exploratory trial

### Acronym

PROACTIVE

### Study objectives

Primary Hypothesis:

PROACTIVE will reduce anxiety and improve wellbeing compared to Treatment As Usual (TAU).

Secondary Hypotheses:

1. PROACTIVE will improve quality of life compared to TAU.
2. PROACTIVE will reduce the number on AS converting to radical intervention (triggered by anxiety) without a clinical (pathological) indication

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Oxfordshire Research Ethics Committee, 24/02/2015, ref: 11/SC/0355

### Study design

A mixed methods randomized parallel-group exploratory trial to determine the feasibility of delivering PROACTIVE within two NHS prostate cancer clinics

### Primary study design

Interventional

### Study type(s)

Quality of life

### Health condition(s) or problem(s) studied

Men with localised prostate cancer being managed with active surveillance

### Interventions

Intervention Group: The intervention group will receive a 6 week psycho-education group based support programme called PROACTIVE. PROACTIVE involves 2 individual interdependent

components:

**1. Group Sessions**

3 group sessions (8-10 men) facilitated by a prostate cancer clinical nurse specialist (CNS). Each session addressing one of 3 themes identified by men on AS as important (Pickles et al., 2007; Hedestig et al., 2008):

1.1.Lack of information

1.2. Uncertainty

1.3. Anxiety and distress

**2. Internet Sessions**

6 internet sessions run weekly on the LifeGuide platform designed to support and complement the group sessions (lifestyle, relaxation techniques, communication, thoughts and feelings, daily life).

**Control Group:** The control group for this study will receive routine care. At the completion of the study all individuals randomised to the control group will be offered free and on-going access to the PROACTIVE website.

**Intervention Type**

Behavioural

**Primary outcome(s)**

1. Hospital Anxiety and Depression Scale (HADS): A validated and reliable 14 item questionnaire that has been used extensively within the field of oncology to assess depression and anxiety
2. Warwick/Edinburgh Mental Wellbeing Scale (WEMWBS): is a validated and reliable measure of mental wellbeing
3. Freiburg Mindfulness Inventory: a valid and reliable 30-item scale that is designed to measure the concept of mindfulness
4. EORTC-QLQ-OV28: A widely used, valid and reliable questionnaire that assesses quality of life specific to ovarian cancer

These will be collected at baselines, 6-weeks (end of intervention) and 6 and 12 months follow-up

**Key secondary outcome(s)**

N/A

**Completion date**

01/12/2017

**Eligibility**

**Key inclusion criteria**

1. Low or intermediate risk PCa (NICE definition 2014)
2. Willing to participate/provide informed consent
3. Diagnosed at least 2-month prior to entry
4. On AS under 12 months.
5. Have received only 1 MRI
6. Fluent English (questionnaires validated in English)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Male

**Key exclusion criteria**

1. Additional cancers
2. Co-morbidities that could significantly impact upon mood
3. Other conflicting research

**Date of first enrolment**

01/10/2015

**Date of final enrolment**

01/10/2016

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre****University of Southampton**

Primary Medical Care  
Aldermoor Health Centre  
Aldermoor Close  
Southampton  
United Kingdom  
SO16 5ST

**Study participating centre****University College London Hospitals NHS Trust Foundation**

UCH Macmillan Cancer Centre  
Huntley Street  
London  
United Kingdom  
WC1E 6AG

# Sponsor information

## Organisation

University of Southampton

## ROR

<https://ror.org/01ryk1543>

# Funder(s)

## Funder type

Charity

## Funder Name

Prostate Cancer UK

## Alternative Name(s)

Prostate Cancer, Prostate Action, ProstateUK, prostatecanceruk

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		11/09/2019	06/08/2024	Yes	No
<a href="#">Other publications</a>	Intervention development	09/08/2022	10/08/2022	Yes	No
<a href="#">Plain English results</a>				No	Yes